Taysha announces pricing of public offering of common stock

Dallas, oct. 26, 2022 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha) (“taysha”), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced the pricing of an underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $2.00 per share. in addition, taysha has granted the underwriter a 30-day option to purchase up to 2,100,000 additional shares of common stock at the public offering price, less the underwriting discount. the gross proceeds from the offering to taysha are expected to be approximately $28.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriter's option to purchase additional shares. the offering is expected to close on or about october 31, 2022, subject to customary closing conditions.
TSHA Ratings Summary
TSHA Quant Ranking